Avalo Therapeutics, Inc.
AVTX
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.0B
$19.23
▲ +1.21%
P/E
-4.06
Mkt Cap
$1.0B
52-Wk Range
$9.54–$24.27
52-Week Range
$9.54 - $24.27
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 68.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Precision medicine approach targeting specific patient populations
- Fully human monoclonal antibody platform reducing immunogenicity risk
- Multiple late-stage clinical programs providing diversified pipeline value
- Focused development in underserved rare genetic disease markets
Bear Case
1 risk
- Low volatility (beta 0.8).
Growth
Stable outlook
Phase III clinical trial progression for rare genetic disease candidates AVTX-801 and AVTX-803
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+50.9% over 3m
Quality
Mixed
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying AVTX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 6, 2026
Reported EPS of -$0.83 vs -$0.58 consensus (-42.4% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-42.4%
Revenue trend · last 8Q
—
—
—
—
-100%
-69%
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$249.0K
$192.0K
$0
$0
$0
$59.0K
$0
$0
Margins · last 8Q
Gross
—
Profit
—
Wall Street consensus
7 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Bank of America · Jun 12, 2026
vs Industry
How AVTX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related